Schwinger W, Urban C, Mache C J, Resch B, Lackner H, Höfler G, Beham-Schmid C, Gilli R, Wagner K, Haas O A
Division of Hematology-Oncology, Children's Clinic, University of Graz, Austria.
Pediatr Hematol Oncol. 1995 Jan-Feb;12(1):47-54. doi: 10.3109/08880019509029527.
Two children with Ph+ chronic myelogenous leukemia (CML) relapsed in the chronic phase after allogeneic bone marrow transplantation (BMT). They were treated with transfusions of peripheral blood mononuclear cells (PBMC) obtained from the former bone marrow donors in combination with interferon alfa-2. In one child, CML was successfully controlled as shown by disappearance of Ph+ metaphases as well as negativity for BCR-ABL fusion gene transcripts demonstrated by polymerase chain reaction (PCR) analysis. The patient has remained in complete remission without evidence of disease for 12 months after donor PBMC transfusions. The other child showed disappearance of BCR-ABL gene transcripts by PCR analysis only in peripheral blood cells, but PCR positivity persisted in bone marrow samples. These results indicate that adoptive immunotherapy may be a further alternative in children with relapse of CML after allogeneic BMT as previously described for adult patients.
两名Ph+慢性粒细胞白血病（CML）患儿在异基因骨髓移植（BMT）后慢性期复发。他们接受了来自前骨髓供体的外周血单个核细胞（PBMC）输注，并联合使用α-2干扰素进行治疗。在一名患儿中，CML得到成功控制，表现为Ph+中期细胞消失，以及聚合酶链反应（PCR）分析显示BCR-ABL融合基因转录本呈阴性。该患者在输注供体PBMC后已持续完全缓解12个月，无疾病证据。另一名患儿经PCR分析仅在外周血细胞中显示BCR-ABL基因转录本消失，但骨髓样本中PCR仍呈阳性。这些结果表明，过继性免疫疗法可能是异基因BMT后CML复发患儿的另一种治疗选择，此前已有针对成年患者的相关描述。
